Track topics on Twitter Track topics that are important to you
Foamix Pharmaceuticals intends to market its acne treatment by itself.
Foamix Pharmaceuticals has reported positive top-line results from the Phase III programme of FMX103 1.5% minocycline foam being assessed for moderate-to-severe...Read More... The post Foamix Phase I...
Foamix Pharmaceuticals has completed patient enrolment and dosing in the FX2016-11 and FX2016-12 studies designed to treat moderate-to-severe papulopustular rosacea....Read More... The post Foamix com...
Clinical stage dermatology-focused Foamix Pharmaceuticals has announced top line results from a phase III study into its FMX103, which is...Read More... The post Foamix publishes top line phase III re...
Foamix Pharmaceuticals’ FMX103 (1.5% topical minocycline foam) has experts split over the drug’s real-world ability to protect against sunburn, despite...Read More... The post Foamix’s rosacea d...
Market of dermatologists prescribing for rosacea and acne is very focused, so Foamix says it can manage commercialization of topical...
Foamix Pharmaceuticals (NASDAQ:FOMX) a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical therapies to address unmet needs in dermatology, to...
Foamix Pharmaceuticals Ltd said on Wednesday its experimental foam treatment for rosacea, a common skin condition that causes acne-like bumps and redness on the face, met the main goals of two late-st...
Foamix Ltd. is a leading developer of topical and mucosal foams for dermatological and gynecological applications. Foamix's state-of-the-art foams provide controlled delivery of a variety of activ...
We have published hundreds of Foamix Ltd news stories on BioPortfolio along with dozens of Foamix Ltd Clinical Trials and PubMed Articles about Foamix Ltd for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Foamix Ltd Companies in our database. You can also find out about relevant Foamix Ltd Drugs and Medications on this site too.
Psoriasis is a common skin condition affecting 2-3% of the population of the United Kingdom, where the skins replacement process is sped taking 2-6 days instead of the usual 21 - 28 days for the replacement of skin cells. Patients experience an accumulat...